Prof Cristofanilli speaks with ecancer at ESMO 2018 in Munich about the analyses of data from the PALOMA-3 study of palbociclib with fulvestrant to treat HR+/HER2- breast cancer, following the previous publication of PFS data.

He outlines the importance of prior sensitisation with endocrine therapy in this population, and recommends the combination as a new standard of care.

For more on this trial, watch his presentation of data at a conference session here: [ Ссылка ]

свернуть